Interleukin-32 positive immune and resident cells in kidney samples from lupus patients: a pilot study

Frontiers in Immunology, Journal Year: 2025, Volume and Issue: 15

Published: Jan. 6, 2025

Lupus nephritis (LN), caused by immune complexes produced in situ or deposited from the bloodstream, is one of most severe features Systemic Erythematosus (SLE) leading to an increased morbidity and mortality. Toll like receptors (TLRs), such as TLR3, TLR7 TLR9, may play a key role its pathogenesis. Interleukin-32 (IL-32), cytokine involved both innate adaptive responses, has been widely considered autoimmune-inflammatory rheumatic diseases. This study aims evaluate IL-32 LN, also investigating effect LN patients IgG (LN-IgG) on production via TLR3. In patients, was detected sera samples ELISA KIT kidney tissue immunohistochemistry. HEK293/T3 cells were incubated with LN-IgG analyzed for TBK1, phospho-p65 NF-κB Western blot. We demonstrated presence compared SLE without renal involvement, observing direct correlation between serum levels disease duration (p=0.02; r 0.2978). Moreover, strongly expressed patients. Phosphorylation TBK1 resulting activation increase observed following treatment, TLR3 inhibitor using induced significant reduction expression these molecules. These results showed that up-regulated suggesting could be through patients' antibodies. indicate possible pathogenesis LN.

Language: Английский

---

Antiphospholipid Antibodies and COVID‐19: A Systematic Review of Clinical Implications

Immunity Inflammation and Disease, Journal Year: 2025, Volume and Issue: 13(2)

Published: Feb. 1, 2025

ABSTRACT Introduction As the COVID‐19 pandemic transitions, understanding intricate dynamics of disease becomes paramount. This systematic review explores role antiphospholipid antibodies in COVID‐19, focusing on their potential clinical implications. Methods review, following PRISMA guidelines, assesses studies exploring link between and COVID‐19. PubMed/Medline, Embase, Scopus were searched for relevant published up to December 22, 2024. Inclusion criteria comprised involving patients diagnosed with reporting presence antibodies. The risk bias individual was evaluated using Joanna Briggs Institute appraisal tool. Results Our Study includes 59 records a total 28,489 patients. Antiphospholipid tested 14,498 It observed that 50.84% positive Various types antibodies, including Anticardiolipin, Anti beta2 glycoproteins, Lupus anticoagulant antibody, displayed prevalence rates thrombosis. overall frequency thrombosis 38.55%. Conclusion significant proportion underscores need detailed investigation into thrombotic events. study highlights avenues targeted interventions. However, evolving nature necessitates continued research efforts clarify implications optimize management strategies this complex landscape immunology. reveals some limitations, such as variability designs demographics inherent differences methodologies among included studies. Future should address these limitations standardized more conclusive findings.

Language: Английский

---

Coronavirus disease 2019 and catastrophic antiphospholipid syndrome: Case report

Medicine, Journal Year: 2025, Volume and Issue: 104(13), P. e41790 - e41790

Published: March 28, 2025

Rationale: The emergence of catastrophic antiphospholipid syndrome (CAPS) alongside coronavirus disease 2019 (COVID-19) is great concern, because its high mortality and unclear mechanism. This severe disease, characterized by multiple thrombi multisystem disorder, has notably diverse clinical presentations, which complicates diagnosis in practice. Now, we report a rare case CAPS patient with COVID-19. Patient concerns: A 64-year-old who mainly presented pain swelling 2 months ago progressed gradually into thrombi, including pulmonary embolism, renal deep vein thrombosis; transient ischemic attack; organ dysfunction acute kidney injury; necrosis both lower limbs, left upper extremity, ears, penile gangrene. Diagnoses: He was diagnosed as COVID-19 positive respiratory coronavirus-2 (SARS-CoV-2) testing high-titer immunoglobulin (Ig) anti-β2-glycoprotein I antibody (anti-β2GPI). Interventions: Active rescue treatments such anticoagulants, plasmapheresis, glucocorticoid pulse therapy, antibiotics, multi-organ functional support alleviated the effectively. Outcomes: Although his symptoms were successfully controlled, could not save necrotic tissue. refused to undergo limb amputation died tissue infection. Lessons: patients an extremely serious rate. delay treatment can result potentially devastating consequences. Therefore, physicians should be alert possibility Furthermore, this serves foundation upon future studies build investigate possible mechanisms IgA anti-β2GPI-positive COVID-19, may guide exploration potential therapeutic strategies prevent disease’s progression.

Language: Английский

---

The Influence of SARS-CoV-2 Infection on the Development of Selected Neurological Diseases

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(16), P. 8715 - 8715

Published: Aug. 9, 2024

In 2024, over 775 million cases of COVID-19 were recorded, including approximately 7 deaths, indicating its widespread and dangerous nature. The disease is caused by the SARS-CoV-2 virus, which can manifest a wide spectrum symptoms, from mild infection to respiratory failure even death. Neurological such as headaches, confusion, impaired consciousness, have also been reported in some patients. These observations suggest potential invade central nervous system induce neuroinflammation during infection. This review specifically explores relationship between selected neurological diseases multiple sclerosis (MS), ischemic stroke (IS), Alzheimer's (AD). It has observed that virus increases production cytokines whose action cause destruction myelin sheaths nerve cells. Subsequently, body may synthesize autoantibodies attack cells, resulting damage brain's anatomical elements, potentially contributing onset sclerosis. Additionally, exacerbates inflammation, worsening clinical condition individuals already suffering MS. Moreover, secretion pro-inflammatory lead an escalation blood clot formation, result thrombosis, obstructing flow brain precipitating stroke. AD characterized intense inflammation heightened oxidative stress, both are exacerbated demonstrates enhanced cell entry presence ACE2 receptor, elevated ApoE ε4 allele. Consequently, worsens progresses more rapidly, increasing mortality rate among above information underscores numerous connections diseases.

Language: Английский

---

ANTIPHOSPHOLIPID ANTIBODIES IN NEW CORONAVIRUS INFECTION: IMPLICATIONS FOR PATIENT CARE

Bulletin of Medical Science, Journal Year: 2024, Volume and Issue: 33(1), P. 115 - 120

Published: Jan. 1, 2024

The new coronavirus infection (COVID-19) is considered a systemic disease, often complicated by thrombotic events, impacting respiratory, cardiovascular, gastrointestinal, hematopoietic, and immune systems. development of hypercoagulable state accompanying the disease involves inflammatory reactions, endothelial dysfunction, hemostatic system activation, autoimmune disorders, including antiphospholipid antibodies (aPA). Despite high prevalence aPA in COVID-19 patients, its impact on complications outcome not significant. transient nature these conflicting study results suggest uncertainty about their influence clinical outcomes patients.

Language: Английский

---

A study of fibrinolytic system components in donor groups depending on various titers of circulating anti-SARS-CoV-2 IgG in the bloodstream

Blood Coagulation & Fibrinolysis, Journal Year: 2023, Volume and Issue: unknown

Published: Aug. 10, 2023

The fibrinolytic system plays an important role in controlling blood coagulation at each stage, from thrombin generation to fibrin clot cleavage. Currently, long-term multiorgan dysfunction post-coronavirus disease 2019 (COVID-19) may include disorders. Little information is available about the potential causes of post-COVID-19 coagulopathy, but one them be subpopulation IgG produced by immune against SARS-CoV-2. This article describes changes main parameters donors with various titers anti-SARS-CoV-2 IgG, which part a complex study hemostasis these donor groups. We determined most significant system, such as activity and amount plasminogen tissue activator (tPA), inhibitor-1 (PAI-1), inhibitory potentials α-2-antiplasmin, α-1-antitrypsin, α-2-macroglobulin plasma obtained results represent maximum minimum values measurement among groups least 10 ± 3 Index (S/C), their statistical differences reference point [donor group titer 0 (S/C)]. established depending on IgG. One conclusion can drawn this: population influence period. Further research in-vitro in-vivo experimental models using selected purified confirm our previous findings.

Language: Английский

---

Prevalence of antiphospholipid antibodies in COVID-19 patients: A meta-analysis

Vascular Pharmacology, Journal Year: 2024, Volume and Issue: unknown, P. 107444 - 107444

Published: Dec. 1, 2024

Language: Английский

---

Autoantibodies in hospitalised patients with COVID‐19

Clinical & Translational Immunology, Journal Year: 2024, Volume and Issue: 13(12)

Published: Jan. 1, 2024

CD209L and its homologous protein CD209 act as alternative entry receptors for the SARS-CoV-2 virus are highly expressed in virally targeted tissues. We tested presence clinical features of autoantibodies targeting these compared with known to be associated COVID-19. Using banked samples (n = 118) from Johns Hopkins patients hospitalised COVID-19, we defined against by enzyme-linked immunosorbent assay (ELISA). Clinical associations antibodies were those anti-interferon (IFN) anti-angiotensin-converting enzyme-2 (ACE2) autoantibodies. Amongst 19.5% (23/118) had IgM more likely have coronary artery disease (44% vs 19%, P 0.03). Antibodies present 5.9% (7/118); interestingly, all 7 male (P 0.02). In our study, either antibody was positively severity [OR 95% confidence interval (95% CI): 1.80 (0.69-5.03)], but association did not reach statistical significance. contrast, 10/118 (8.5%) IgG IFNα, 21 (17.8%) ACE2. These significantly worse prognosis (intubation or death) prolonged hospital stays. However, when adjusting patient characteristics on admission, only anti-ACE2 remained significant [pooled common OR CI), 4.14 (1.37, 12.54)]. describe amongst severity. Conversely, anti-IFNα outcomes. Due small size study cohort, conclusions drawn should considered cautiously.

Language: Английский

---